IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Milano.

AIR nasce in UNIMI nel 2006 con lo scopo di raccogliere, documentare e conservare le informazioni sulla produzione scientifica dell'Università degli Studi di Milano e costituisce di fatto l'Anagrafe della ricerca dell'Ateneo.

In summary, targeted drugs, primarily the EGFR inhibitors, have added new effective agents to the therapeutic armamentarium for NSCLC. Qualitative and quantitative survival benefit has been demonstrated with small molecules TKIs, but also anti-EGFR monoclonal antibodies, even though in an earlier stage of clinical investigation, have demonstrated promising activity that warrants further studies of these agents. Mutations in the ATP-binding site, that have been consistently associated with clinical response to TKIs [11], do not seem to predict response to anti-EGFR therapy using monoclonal antibodies such as cetuximab [4, 12]. Moreover, it has recently been reported that two patients responded to gefitinib after failure of several chemotherapy regimens and cetuximab [15]. Taken together, these findings could suggest that monoclonal antibodies and TKIs have different mechanisms of action and might be effectively combined in order to broaden their spectrum of activity.

Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer / A. Sartore-Bianchi, G. Cerea, I. Schiavetto, L. Giannetta, R. Ricotta, M.R. Maugeri, M. Moroni, G. Marrapese, S. Siena. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 17:suppl. 2(2006), pp. ii49-ii51. ((Intervento presentato al 12. convegno National AIOM Comference tenutosi a Roma nel 2006.

Powered by IRIS-about IRIS-Utilizzo dei cookie

 Copyright © 2021